METROPOLIS595.00

Metropolis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABVIJAYATHYROCAREMARKSANSPARKHOSPSJLHLRUBICONHCGMcap ₹12,336 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
METROPOLIS
FY26
LALPATHLAB
FY26
VIJAYA
FY26
THYROCARE
FY26
Peer
Median
Valuation — at last close
P/E64.74×63.23×89.41×54.33×63.23× +2%
P/B8.09×12.61×16.16×15.15×15.15× -47%
EV/EBITDA30.33×40.10×45.10×33.17×40.10× -24%
Market Cap₹12,336 Cr₹32,045 Cr₹15,465 Cr₹8,882 Cr₹15,465 Cr -20%
Growth
Revenue CAGR 3Y12.75%11.06%21.03%16.33%16.33% -22%
Revenue CAGR 5Y10.52%11.81%16.66%10.88%11.81% -11%
Net Income CAGR 3Y10.06%28.35%26.62%36.27%28.35% -65%
Revenue YoY (latest Q)16.62%19.10%22.83%24.34%22.83% -27%
Net Income YoY (latest Q)25.72%27.24%37.61%34.06%34.06% -24%
Profitability
EBITDA Margin24.36%28.32%41.38%31.61%31.61% -23%
Net Income Margin11.62%18.45%21.24%19.64%19.64% -41%
Return on Common Equity12.46%19.86%18.07%27.82%19.86% -37%
Return on Capital Employed14.81%23.03%17.72%31.92%23.03% -36%
Return on Assets8.94%16.20%11.48%21.79%16.20% -45%
Credit & Quality
Total Debt/Equity0.01×0.00×0.00×0.00×0.00×
Interest Coverage10.88×27.22×7.38×72.66×27.22× -60%
Scale — latest FY
Revenue / Total Income₹1,646 Cr₹2,763 Cr₹814 Cr₹829 Cr₹829 Cr +99%
Net Income₹191 Cr₹510 Cr₹173 Cr₹163 Cr₹173 Cr +11%
Total Assets₹2,138 Cr₹3,146 Cr₹1,507 Cr₹747 Cr₹1,507 Cr +42%
EPS₹9.19₹30.24₹16.81₹10.27₹16.81 -45%
Book Value per Share₹73.53₹151.63₹93.02₹36.82₹93.02 -21%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.